Government Approves Skymap Pharmaceuticals’ ₹121 Crore Acquisition of IMPCL Through Strategic Disinvestment Process

The Government of India has approved the strategic sale of Indian Medicines Pharmaceutical Corporation Limited (IMPCL) to Skymap Pharmaceuticals Private Limited for ₹121.01 crore. The transaction involves the transfer of 100% equity shareholding along with management control of the state-run pharmaceutical company under the Ministry of Ayush. The approval follows a multi-stage competitive bidding process that began with the government’s strategic disinvestment initiative and culminated in Skymap Pharmaceuticals emerging as the highest bidder above the reserve price.

Key Takeaways: IMPCL Strategic Sale to Skymap Pharmaceuticals

• The government approved the sale of 100% equity stake in IMPCL to Skymap Pharmaceuticals Pvt Ltd.
• The winning bid stood at ₹121,00,94,400, above the reserve price.
• The transaction includes transfer of management control.
• IMPCL operates under the Ministry of Ayush and manufactures Ayurvedic and Unani medicines.
• The company has a manufacturing facility in Almora, Uttarakhand.
• Seven entities initially expressed interest in the disinvestment process.
• Two financial bids were received and evaluated in January 2026.
• The Letter of Award has been issued to Skymap Pharmaceuticals.
• DIPAM and the Ministry of Ayush have been authorised to complete the transaction.
• The deal forms part of the government’s broader strategic disinvestment and asset monetisation programme.

Government Clears Strategic Sale of IMPCL

The government on Tuesday approved Delhi-based Skymap Pharmaceuticals Private Limited’s bid of ₹121.01 crore for the strategic sale of Indian Medicines Pharmaceutical Corporation Limited (IMPCL), a public sector undertaking under the administrative control of the Ministry of Ayush.

An inter-ministerial panel approved the sale of the government’s entire equity stake in IMPCL along with transfer of management control. According to the Finance Ministry, Skymap Pharmaceuticals emerged as the highest bidder with an offer of ₹121,00,94,400, which was also above the reserve price fixed for the transaction.

Also Read:  Medical Science and Its Wonders Transforming Health, Healing, and Human Life

The approval was granted by the Alternative Mechanism, a group of ministers empowered by the Cabinet Committee on Economic Affairs (CCEA). The panel comprises the Union Finance Minister, the Union Minister for Road Transport and Highways, and the Minister of State (Independent Charge) for Ayush.

IMPCL Profile and Operations

IMPCL was incorporated in 1978 and functions under the Ministry of Ayush. The company was established to manufacture and supply standardised Ayurvedic and Unani medicines.

The state-run pharmaceutical company operates a manufacturing facility in Almora, Uttarakhand, and has played a role in the production of traditional medicine formulations.

IMPCL at a Glance

Strategic Disinvestment Process

Reports stated that the strategic disinvestment process for IMPCL was initiated around three years ago. Earlier, the Cabinet Committee on Economic Affairs had granted in-principle approval for the strategic sale of the government’s stake in the company through a competitive bidding route.

The Union Cabinet had approved the sale of the government’s entire stake in IMPCL in 2017, while the CCEA granted in-principle approval for the strategic sale in November 2017.

The transaction was implemented through a two-stage competitive bidding process supported by a multi-layered consultative decision-making mechanism involving an inter-ministerial group, the Core Group of Secretaries on Disinvestment, and the empowered Alternative Mechanism.

Bidding Timeline and Evaluation Process

The Department of Investment and Public Asset Management (DIPAM) invited Expressions of Interest from prospective bidders in September 2023 through the issuance of a Preliminary Information Memorandum.

Seven entities initially submitted expressions of interest. All seven were subsequently shortlisted as qualified interested bidders for the next stage of the process.

Following due diligence exercises and security clearances from the Ministry of Home Affairs, Request for Proposal documents and Share Purchase Agreement terms were issued to qualified bidders in December 2025.

The government then invited technical and financial bids. By January 20, 2026, two financial bids had been received. Both bids were evaluated according to the prescribed procedure and were found technically qualified.

Thereafter, the technically qualified financial bids were opened in the presence of representatives of the bidders.

Timeline of the IMPCL Sale Process

Skymap Pharmaceuticals Emerges as Highest Bidder

Skymap Pharmaceuticals Private Limited emerged as the highest bidder in the competitive process. The company was incorporated in 2006 and manufactures pharmaceutical formulations including injectables, tablets, capsules and other dosage forms.

The company has operations in domestic and export markets. According to the company’s official website, Skymap was founded by Sanjay Gupta and maintains a portfolio of more than 500 products. The company also operates manufacturing facilities and exports products to overseas markets.

The government has issued the Letter of Award to Skymap Pharmaceuticals. Secretary, DIPAM and Secretary, Ayush have been authorised to complete and close the transaction at the earliest.

Significance of the Transaction in the Government’s Disinvestment Programme

The strategic sale marks a significant disinvestment transaction involving a government-owned pharmaceutical company operating in the Ayurvedic and Unani medicines sector.

The development also comes as the government has set a disinvestment and asset monetisation target of ₹80,000 crore for FY27. Reports noted that the government continues to focus on strategic disinvestment and monetisation initiatives as part of its broader asset monetisation programme.

Next Steps in the IMPCL Transaction

With the Letter of Award already issued, the focus now shifts to completion of the transaction process by the authorised government departments. The sale represents the culmination of a multi-stage strategic disinvestment exercise involving several government bodies, evaluation committees and regulatory clearances. Upon completion, Skymap Pharmaceuticals will acquire 100% equity ownership and management control of IMPCL, bringing the state-run Ayurvedic and Unani medicines manufacturer under private ownership.

Ethical Stewardship and Public Responsibility

The strategic sale of a public-sector enterprise highlights the broader responsibility that accompanies ownership, management, and decision-making. Beyond financial transactions and institutional changes, long-term value is often linked to transparency, accountability, and service to society. 

According to the spiritual teachings of Tatvadarshi Saint Rampal Ji Maharaj, sustainable progress is strengthened when decisions are guided by ethical conduct, honesty, and welfare-oriented thinking. Such principles encourage individuals and institutions alike to balance material development with responsible action for the larger good.

For more information visit our:

Website: www.jagatgururampalji.org 

YouTube: Sant Rampal Ji Maharaj

Facebook: Spiritual Leader Saint Rampal Ji

X (Twitter): @SaintRampalJiM

FAQs on IMPCL Strategic Sale

1. What is IMPCL?

IMPCL is Indian Medicines Pharmaceutical Corporation Limited, a PSU under the Ministry of Ayush that manufactures Ayurvedic and Unani medicines.

2. Who acquired IMPCL?

Skymap Pharmaceuticals Private Limited emerged as the highest bidder and received government approval to acquire IMPCL.

3. What was the winning bid amount?

The approved bid amount was ₹121,00,94,400, or approximately ₹121.01 crore.

4. What does the transaction include?

The sale includes 100% equity shareholding in IMPCL along with transfer of management control.

5. When did the disinvestment process begin?

The strategic disinvestment process gained momentum after in-principle approval in November 2017, with EOI invited in September 2023.